Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luvixasertib - Treadwell Therapeutics

Next Previous
Drug Profile

Luvixasertib - Treadwell Therapeutics

Alternative Names: CFI-402257

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University Health Network
  • Developer Treadwell Therapeutics; University Health Network
  • Class Antineoplastics; Benzamides; Cyclopropanes; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase I/II HER2 negative breast cancer; Solid tumours

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Canada (PO)
  • 06 Dec 2023 Luvixasertib - Treadwell Therapeutics is available for licensing as of 06 Dec 2023
  • 05 Dec 2023 Efficacy and adverse events data from a phase Ib/II TWT 203 trial in HER2-negative-breast-cancer and Solid tumours presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top